Sökresultat

Filtyp

Din sökning på "*" gav 560625 sökträffar

Kontakt

Institutionsledning PrefektElin A. Toppelin_a [dot] topp [at] cs [dot] lth [dot] se (elin_a[dot]topp[at]cs[dot]lth[dot]se)Ställföreträdande prefektPer Runesongorel [dot] hedin [at] cs [dot] lth [dot] se (per[dot]runeson[at]cs[dot]lth[dot]se) Studierektorer GrundutbildningPer Anderssonper [dot] andersson [at] cs [dot] lth [dot] se (per[dot]andersson[at]cs[dot]lth[dot]se)ForskarutbildningMichael Dog

https://www.cs.lth.se/kontakt - 2026-04-17

Skicka in ett exjobbsförslag – Högskoleingenjörer

Studenter på LTH:s högskoleingenjörsprogram kan här skicka in exjobbsförslag och därmed ansöka om handledning av exjobb på institutionen för Datavetenskap. Förslag som omfattar två studenter skickas in som ett gemensamt förslag, inte en inskickning per student.Läs först instruktionerna på Canvas-sidan Exjobbet steg-för-steg.Skriv gärna på engelska då det maximerar antalet presumtiva handledare som

https://www.cs.lth.se/formular/skicka-ett-exjobbsforslag-hogskoleingenjorer - 2026-04-17

Skicka in ett exjobbsförslag – Civilingenjörs- och Masterprogram

Studenter på LTHs Civilingenjörs- och Masterprogram kan här skicka in exjobbsförslag och därmed ansöka om handledning av exjobb på institutionen för Datavetenskap. Förslag som omfattar två studenter (enligt prioriterad policy) skickas in som ett gemensamt förslag, inte en inskickning per student.Läs först instruktionerna på Canvas-sidan Exjobbet steg-för-steg.Skriv gärna på engelska då det maximer

https://www.cs.lth.se/formular/skicka-ett-exjobbsforslag-civilingenjors-och-masterprogram - 2026-04-17

Anmäl presentation

Fyll i formuläret för att anmäla ditt examensarbete vid Institutionen för datavetenskap. Om ni har arbetat i par behöver ni inte anmäla presentationen två gånger. Det räcker med en anmälan per presentation.Sista anmälningsdag framgår på Canvas-sidan Gemensamma presentationsdagar och anmäl presentation.Eventuella frågor skickas till exjobb [at] cs [dot] lth [dot] se (exjobb[at]cs[dot]lth[dot]se). D

https://www.cs.lth.se/formular/anmal-presentation - 2026-04-17

Breakfast seminar: To Trust, or Not to Trust? That is the Question with Amir Aminifar

22 april 2026 09:00 till 10:00 | Seminarium Welcome to join WASP Lighthouse and AI & Digitalization breakfast seminar with Amir Aminifar, on how trust in AI/ML systems can be built, talk titled "To Trust, or Not to Trust? That is the Question." Breakfast is served at 09:00, the presentation will start shortly after. For breakfast, please sign up no later than April 20: Sign up here. Recent researc

https://www.cs.lth.se/evenemang/breakfast-seminar-trust-or-not-trust-question-amir-aminifar - 2026-04-17

Gustaf Waldemarson's PhD defence

24 april 2026 13:15 | Disputation The public defence of the thesis takes place on Friday April 24th, 2025 at 13:15 in E:1406 Thesis title: Rendering Small Things: Hardware Micromaps and ParticlesAuthor: Gustaf Waldemarson, Department of Computer Science, Lund UniversityFaculty opponent: Associate Professor Jeppe Frisvad, DTU Technical University of Denmark, DenmarkExamination Committee:Professor I

https://www.cs.lth.se/evenemang/gustaf-waldemarsons-phd-defence - 2026-04-17

Peng Kuang's PhD defence

13 maj 2026 13:00 | Disputation The public defence of the thesis takes place on Wednesday May 13th, 2025 at 13:00 in E:1406 Thesis title: Building Gaze-aware Programming EnvironmentsAuthor: Peng Kuang, Department of Computer Science, Lund UniversityFaculty opponent: Associate Professor Andrew Begel, Carnegie Mellon University, USAExamination Committee:Professor Yvonne Dittrich, IT University of Co

https://www.cs.lth.se/evenemang/peng-kuangs-phd-defence - 2026-04-17

Start

CREATE Health: Translational Cancer Center CREATE Health develops and translates cutting-edge diagnostic and therapeutic innovations into real-world clinical solutions that measurably improve patient outcomes and advance public health. We combine state-of-the-art technologies, including AI-driven data analytics, next-generation sequencing, advanced molecular imaging, precision biologics and target

https://www.createhealth.lth.se/start - 2026-04-17

Organisation

Centre Management Sara EkCenter Directorsara [dot] ek [at] immun [dot] lth [dot] se (sara[dot]ek[at]immun[dot]lth[dot]se) Kristina LundbergDeputy Directorkristina [dot] lundberg [at] immun [dot] lth [dot] se (kristina[dot]lundberg[at]immun[dot]lth[dot]se) Corinna RichterResearch Coordinatorcorinna [dot] richter [at] immun [dot] lth [dot] se (corinna[dot]richter[at]immun[dot]lth[dot]se) Board Carl

https://www.createhealth.lth.se/about/organisation - 2026-04-17

Impact

Collaboration, commercialisation as well as high-impact publications allow to accelerate translation of breakthrough therapies and diagnostics into clinical practice. Principle Investigators within CREATE Health have founded several spin-off companies which are already helping patients all around the world.  Beside that, tens of research articles with ground-breaking discoveries have been publishe

https://www.createhealth.lth.se/impact - 2026-04-17

Recruitment

Open positions will be advertised on Lund University's website and on our social media channels.If you are a student and interested in doing a Master's or ExJobb project, please contact the PI of the group of interest directly.

https://www.createhealth.lth.se/about/recruitment - 2026-04-17

Partners

Links will open on the respective websites.Region SkåneMedicon VillageCHUV in LausanneTMUCI in Tianjin, ChinaOslo Cancer ClusterWorking together is an integral part of CREATE Health’s DNA. We can proudly say that CREATE Health’s researchers are highly engaged in many different collaborations and networks – too many to name all of them here. For detailed information on our researchers’ collaborativ

https://www.createhealth.lth.se/about/partners - 2026-04-17

Spin-off companies

Lead BiologicsLead Biologics was founded in 2022 by Thoas Fioretos, Carl Sandén and Marcus Järås (Lund University), Kjell Sjöström (Innovagen) and Niklas Landberg (SUS). The company combines state-of-the-art technologies with unique patient cohorts to identify multiple novel therapeutic targets in leukemias and solid tumors. The aim is to develop a first-in-class treatment against SLAMF6. A majors

https://www.createhealth.lth.se/impact/spin-companies - 2026-04-17

CanFaster

The Translational Cancer Faster Forward doctoral/postdoctoral programmes (2018-2025). The CanFaster programme is supported by the European Union’s Marie Skłodowska-Curie COFUND programme (Horizon 2020 framework) based on the "Mobility across borders" philosophy. The CanFaster programme has attracted international PhD and Postdoc fellows (ER) with an interest in applied medical research in oncology

https://www.createhealth.lth.se/impact/canfaster - 2026-04-17

CanFaster Publications

The links below open on the respective publication website.In vivo dendritic cell reprogramming for cancer immunotherapy.Authors: Ascic, E., Catena, X., et al.Publication: Science 386, 6719Year: 2024Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.Authors: Meng, P., Dalal, H., Chen, Y., Brueffer, C., Gladchuk, S., Alcaide, M., ... &

https://www.createhealth.lth.se/impact/canfaster/canfaster-publications - 2026-04-17

Inducing anti-tumor immunity with in-situ direct reprograming of cancer cells to cDC1s

Immunotherapy has transformed the cancer treatment landscape leading to long-term responses. However, these strategies are effective in a limited number of patients and often lose their efficacy as the tumor progresses. Insufficient antigen presentation mediated by MHC downregulation and exclusion of functional antigen-presenting cells (APCs) from the tumor microenvironment (TME) are critical evas

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/inducing-anti-tumor-immunity-situ-direct-reprograming-cancer-cells-cdc1s - 2026-04-17

Next generation immuno-oncological targets for cancer therapy

Immuno-oncological (I-O) treatment methods have revolutionized cancer therapy and tremendous clinical benefits are achieved in some cancer patients. However, today a limited number of I-O drug targets are used and only a fraction of all cancer patients has a therapeutic response. We need to further understand the immune system in cancer in order to develop novel treatment strategies and improve su

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/next-generation-immuno-oncological-targets-cancer-therapy - 2026-04-17

Subtype-dependent biomarkers for systemic therapy in bladder cancer

Cancer in the urinary bladder afflicts around 3000 persons per year in Sweden, most often older men and smokers. Despite being a quite common cancer type it is an understudied cancer type considering the burden to society and health outcomes [1].To patients with superficial cancer limited to the mucosa of the urinary bladder, the prognosis is good, but once the tumor has grown into the muscle-laye

https://www.createhealth.lth.se/canfaster/ongoing-canfaster-postdoc-projects/subtype-dependent-biomarkers-systemic-therapy-bladder-cancer - 2026-04-17